Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Cancer Med ; 12(1): 146-158, 2023 01.
Article in English | MEDLINE | ID: mdl-35770957

ABSTRACT

BACKGROUND: Most studies evaluating factors associated with the survival of patients with brain metastases (BM) have focused on patients with newly diagnosed BM. This study aimed to identify prognostic factors associated with survival after brain re-irradiation in order to develop a new prognostic index. METHODS: This 5-year retrospective study included patients treated with repeat-radiotherapy for recurrent BM at the "Instituto Nacional de Cancerología" of Mexico between 2015 and 2019. Significant variables in the multivariate Cox regression analysis were used to create the brain re-irradiation index (BRI). Survival and group comparisons were performed using the Kaplan-Meier method and the log-rank test. RESULTS: Fifty-seven patients receiving brain re-irradiation were identified. Most patients were women (75.4%) with a mean age at BM diagnosis of 51.4 years. Lung and breast cancer were the most prevalent neoplasms (43.9% each). Independent prognostic factors for shorter survival after re-irradiation were: Age >50 years (hazard ratio [HR]:2.5 [95% confidence interval [CI], 1.1-5.8]; p = 0.026), uncontrolled primary tumor (HR:5.5 [95% CI, 2.2-13.5]; p < 0.001), lesion size >20 mm (4.6 [95% CI, 1.7-12.2]; p = 0.002), and an interval <12 months between radiation treatments (HR:4.3 [95% CI, 1.7-10.6]; p = 0.001). Median survival (MS) after re-irradiation was 14.6 months (95% CI, 8.2-20.9).MS of patients stratified according to the BRI score was 17.38, 10.34, and 2.82 months, with significant differences between all groups. CONCLUSIONS: The new BRI can be easily implemented for the prognostic classification of cancer patients with progressive or recurrent BM from extracranial solid tumors.


Subject(s)
Brain Neoplasms , Re-Irradiation , Humans , Female , Middle Aged , Male , Prognosis , Retrospective Studies , Brain Neoplasms/pathology , Proportional Hazards Models
2.
Cureus ; 10(7): e3071, 2018 Jul 30.
Article in English | MEDLINE | ID: mdl-30510860

ABSTRACT

Objective Our objective was to determine whether a delay in adjuvant radiotherapy is related to a decrease in relapse-free survival and disease-specific survival of women with operable breast cancer. Methods Data on 1000 patients diagnosed with breast cancer were recorded. The cohort was divided into five groups according to the timing of radiotherapy: ≤30 days, 31 to 60 days, 61 to 90 days, 91 to 120 days, and >120 days. The relapse-free survival and disease-specific survival were also calculated in relation to the number of patients. Results This study found no statistical difference for delays in adjuvant radiotherapy in patients with early breast cancer, but we noted a statistical decrease in disease-specific survival in patients with locally advanced breast cancer receiving radiotherapy after a delay of at least 60 days. Conclusion Waiting times for radiotherapy should be as short as reasonably achievable, given the specific risk factors in the individual patient.

3.
Rev Invest Clin ; 70(3): 112-116, 2018.
Article in English | MEDLINE | ID: mdl-29943771

ABSTRACT

Mexico has seen an increase in cancer prevalence in its entire population as well as particular age ranges, predominantly the older segment. The most frequently reported pelvic cancers in Mexico are cervical, endometrial, bladder, prostate, rectum, and anal canal. Approximately 80% of the population diagnosed with pelvic cancers present with locally advanced tumors and require concomitant chemoradiotherapy, sequential chemoradiotherapy, or radiotherapy alone. The toxicity of any of these treatment modalities may be manifested as intestinal injury, a significant problem that can compromise the response to treatment, the patient's nutritional state, quality of life, and survival. In this article, we will approach key aspects in nutrition as well as the epidemiological characteristics and toxicities in patients affected by these pelvic tumors.


Subject(s)
Gastrointestinal Diseases/etiology , Pelvic Neoplasms/therapy , Quality of Life , Chemoradiotherapy/adverse effects , Chemoradiotherapy/methods , Gastrointestinal Diseases/physiopathology , Humans , Mexico/epidemiology , Pelvic Neoplasms/epidemiology , Pelvic Neoplasms/pathology , Prevalence , Radiation Injuries/epidemiology , Radiation Injuries/physiopathology
4.
Rev Invest Clin ; 70(3): 126-129, 2018.
Article in English | MEDLINE | ID: mdl-29943774

ABSTRACT

Radiotherapy is a fundamental part of the treatment of pelvic neoplasms. Up to 90% of patients develop gastrointestinal symptoms as a result of acute injury to the small and large intestine, particularly in the mucosa. Radiotherapy leads to atrophy of the intestinal epithelium, acute crypt inflammation, inflammatory infiltration of the epithelium, malabsorption of lactose, and biliary salts as well as alterations in pancreatic enzymes and biliary salts, resulting in the malabsorption syndrome and dysbiosis. The most commonly reported symptoms of pelvic radiation disease include changes in bowel habits (94%), decreased fecal consistency (80%), frequency of bowel movements (74%), bowel urgency (39%), and fecal incontinence (37%). Although nutritional interventions with dietary modifications have been reported to prevent and treat gastrointestinal symptoms, the evidence remains inconclusive.


Subject(s)
Diet , Gastrointestinal Diseases/etiology , Pelvic Neoplasms/therapy , Chemoradiotherapy/adverse effects , Chemoradiotherapy/methods , Gastrointestinal Diseases/epidemiology , Gastrointestinal Diseases/therapy , Gastrointestinal Tract/physiopathology , Humans , Radiation Injuries/epidemiology
5.
Rev Invest Clin ; 69(1): 11-19, 2017.
Article in English | MEDLINE | ID: mdl-28239177

ABSTRACT

BACKGROUND: Radiation therapy is a keystone to improve survival and quality of life in breast cancer patients. In Mexico, however, scarce information is available on the obstacles faced by radio-oncologists to provide appropriate treatment. OBJECTIVE: To determine the most frequent issues faced by physicians to provide radiation therapy for metastatic breast cancer in Mexico. METHODS: A survey of 16 multiple-choice questions to be answered electronically by 167 radio-oncologists currently working in Mexico was designed and thereafter analyzed for differences between private and public practices, based on the responses from the surveyed participants. RESULTS: 98.5% of surveyed responders attended patients with breast cancer. We observed a significant difference between private vs. public practice for the main difficulties in providing radiation therapy, with an increased frequency (85.8%) of "treatment cost by itself" in private practice vs. 50.7% in public practice (p < 0.05). Significant differences were observed in the "Time to initiate treatment" question, with "Less than one week" as the response in 86% of those physicians in private practice vs. 50% for those in public practice (p < 0.001). CONCLUSIONS: Using a survey targeted at radio-oncologists, we analyzed the most important obstacles for accessing radiation therapy for metastatic breast cancer in Mexico. This information may be useful for healthcare decisions related to radiation therapy in women with breast cancer in Mexico.


Subject(s)
Breast Neoplasms/radiotherapy , Practice Patterns, Physicians'/statistics & numerical data , Radiation Oncologists/statistics & numerical data , Breast Neoplasms/pathology , Female , Health Care Surveys , Humans , Mexico , Neoplasm Metastasis , Private Practice/statistics & numerical data , Professional Practice/statistics & numerical data , Quality of Life , Time Factors
6.
Cir. & cir ; 74(5): 381-396, sept.-oct. 2006. tab
Article in Spanish | LILACS | ID: lil-573408

ABSTRACT

El dolor por cáncer es un problema frecuente en nuestro medio, se presenta en 80 a 90 % de los pacientes y en aproximadamente 90 % de ellos se resuelve con medidas relativamente sencillas. No obstante, aproximadamente 40 % de los pacientes se encuentra insatisfecho con el médico o la enfermera respecto al manejo de su dolor. Por tal motivo, se convocó a un grupo de consenso con la finalidad de generar parámetros de práctica clínica fundamentados en la evidencia publicada y en la opinión de los expertos. Este grupo estuvo integrado por 31 médicos líderes de opinión es este campo, quienes con base en 599 documentos emitieron esta serie de recomendaciones, identificadas cada una según su nivel de evidencia.


Cancer pain is a frequent medical problem in our society. This syndrome affects from 80 to 90% of cancer patients and can be solved with relatively simple measures in 90% of the cases. Approximately 40% of cancer patients reported to be unsatisfied with the physician or nurse about their pain management. For these reasons, we gathered a task force in order to generate practice guidelines based on medical evidence and on the opinion of experts in this area. These guidelines were generated by a task force of 31 physicians who were leaders in this field and based on 599 papers selected by a previous literature search. This group evaluated the results of this search in three work sessions, during which a level of evidence was assigned to each recommendation.


Subject(s)
Humans , Analgesia/methods , Analgesics/therapeutic use , Pain/therapy , Neoplasms/physiopathology , Analgesia, Epidural , Adjuvants, Pharmaceutic/administration & dosage , Adjuvants, Pharmaceutic/therapeutic use , Analgesia/standards , Analgesics/administration & dosage , Analgesics/classification , Combined Modality Therapy , Disease Management , Drug Administration Routes , Pain/drug therapy , Pain/etiology , Pain/psychology , Pain/radiotherapy , Pain/surgery , Evidence-Based Medicine , Infusion Pumps, Implantable , Injections, Intraventricular , Physical and Rehabilitation Medicine/methods , Nerve Block , Patient Selection
SELECTION OF CITATIONS
SEARCH DETAIL
...